NCT00442650View on ClinicalTrials.gov

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Moderate to Severe Psoriasis
Interventions
DRUG

Efalizumab

Trial Locations (1)

Unknown

Merck Serono Medical Information Office, Geneva

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT00442650 - Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis | Biotech Hunter | Biotech Hunter